Radiological identification of rapid progressions in advanced NSCLC patients treated with nivolumab.
Explore this paper's citation graph
- Type
- article
- Published
- 2018-10-01
- Cited by
- 1
- References
- 0
- Access
- Open access
- OpenAlex
- https://openalex.org/W2897254871
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:80951207
Keywords
Nivolumab, Medicine, Response Evaluation Criteria in Solid Tumors, Progressive disease, Radiological weapon
References
No references recorded for this paper.
Cited by
Related papers
- Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
- P3.02c-036 Management of Early Disease Progression during Treatment of Advanced Non-Small Cell Lung Cancer with Nivolumab: Topic: IT
- Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
- Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
- Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
- Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer
- RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
- Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors
- Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis